Verrica Pharmaceuticals Debt To Equity Over Time
| VRCA Stock | USD 1.24 0.13 11.71% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Verrica Pharmaceuticals Performance and Verrica Pharmaceuticals Correlation. Verrica |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.198 | Quarterly Revenue Growth 27.445 | Return On Assets (0.71) | Return On Equity (20.60) |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Debt To Equity Analysis
Compare Verrica Pharmaceuticals and related stocks such as LianBio ADR, Inventiva Sa, and Edgewise Therapeutics Debt To Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IVA | 0.0027 | 0.0027 | 0.0027 | 0.0027 | 0.002 | 0.0163 | 0.0176 | 0.0082 | 0.0358 | 0.0019 | 0.0904 | 0.1124 | 0.6598 | (0.9654) | (0.92) |
| EWTX | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0031 | 0.0019 |
| VIGL | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.0126) | 9.0E-4 | 0.0078 | 0.0082 |
| CNTB | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (6.0E-4) | (6.0E-4) | (6.0E-4) | (6.0E-4) | (5.0E-4) | (6.0E-4) |
| ABOS | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 0.1056 | 0.11 |
| ETON | 0.4303 | 0.4303 | 0.4303 | 0.4303 | 0.4303 | 0.4303 | 0.4303 | 0.4303 | 0.4303 | 0.4303 | 0.4497 | 0.3789 | 0.4907 | 0.3476 | 0.46 |
| NUVB | (0.8065) | (0.8065) | (0.8065) | (0.8065) | (0.8065) | (0.8065) | (0.8065) | (0.8065) | (0.8065) | 0.0012 | 0.0012 | 0.0012 | 0.0018 | 0.0033 | 0.0034 |
| ELDN | 0.1283 | 0.1283 | 0.1283 | 0.1283 | 0.1283 | 0.1283 | 0.1283 | 8.0E-4 | 8.0E-4 | 8.0E-4 | 8.0E-4 | 0.0023 | 0.0043 | 0.0531 | 0.0416 |
| VRNA | 0.0294 | 0.0294 | 0.0294 | 0.0294 | 0.0294 | 0.0294 | 0.0294 | 0.0294 | 0.0294 | 0.0294 | 0.0294 | 0.0329 | 0.0424 | 0.1941 | 0.2 |
| ARQT | (0.1935) | (0.1935) | (0.1935) | (0.1935) | (0.1935) | (0.1935) | (0.1935) | (0.1935) | (0.0027) | (0.0027) | 0.2445 | 0.2445 | 0.9468 | 2.2842 | 2.4 |
| PLX | 0.0191 | (2.4882) | (2.4882) | (2.4882) | (1.2134) | 6.6308 | (7.7851) | (1.6677) | (0.9071) | (0.7858) | (2.1642) | (4.8201) | (2.7542) | 0.6452 | 0.68 |
| PLRX | (0.5952) | (0.5952) | (0.5952) | (0.5952) | (0.5952) | (0.5952) | (0.5952) | (0.5952) | (0.5952) | (1.0207) | 0.0094 | 0.0094 | 0.0395 | 0.024 | 0.0252 |
| CRNX | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0342) | (0.0308) | (0.0323) |
| ASND | 0.0079 | 0.0079 | 0.0079 | 0.0079 | 0.0079 | 0.0079 | 0.0079 | 0.0079 | 0.0079 | 0.0079 | 0.0079 | 0.0079 | 1.5158 | (3.7439) | (3.56) |
| FENC | 1.2415 | 0.3163 | 0.3163 | 0.3163 | 0.3163 | 0.3163 | 0.3163 | 0.3163 | 0.3163 | 0.3163 | 0.3163 | 0.3163 | (9.6921) | (2.6614) | (2.79) |
| LRMR | 0.0724 | 0.0724 | 0.0724 | 0.0724 | 0.0724 | 0.0378 | 0.0295 | 0.2557 | 0.2213 | 0.0057 | 0.0057 | 0.0092 | 0.0055 | 0.0063 | 0.006 |
Verrica Pharmaceuticals and related stocks such as LianBio ADR, Inventiva Sa, and Edgewise Therapeutics Debt To Equity description
A measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets.My Equities
My Current Equities and Potential Positions
| Verrica Pharmaceuticals | VRCA |
| Classification | Pharmaceutical Products |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.24
Check out Verrica Pharmaceuticals Performance and Verrica Pharmaceuticals Correlation. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Verrica Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.